[1] Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020,158(7):1851-1864. [2] 倪文婧,李婕,南月敏.非酒精性脂肪性肝病合并糖尿病的综合管理:2024年美国糖尿病学会指南解读.中华肝脏病杂志,2024,32(6):504-507. [3] Tanase DM, Gosav EM, Costea CF,et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res, 2020,31(20):3920-3921. [4] Tao LC, Xu JN, Wang TT,et al. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol, 2022,21(1):68-69. [5] Seetharaman J, Srivastava A, Yadav RR, et al. Visceral fat indices: do they help differentiateCrohn's disease and intestinal tuberculosis in children? J Crohns Colitis, 2023,30(9):109-110. [6] Brenes-Martín F, Melero-Jiménez V, Lopez-Guerrero MA, et al. First trimester evaluation of maternal visceral fat and its relationship with adverse pregnancy outcomes. Biology (Basel). 2023,12(2):144-145. [7] Morys F, Dadar M, Dagher A. Association between midlife obesity and its metabolic consequences, cerebrovascular disease, and cognitive decline. J Clin Endocrinol Metab, 2021,106(10):4260-4274. [8] Hiruma S, Shigiyama F, Hisatake S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol, 2021,20(1):32-33. [9] 中国研究型医院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会,中华医学会肝病学分会脂肪肝与酒精性肝病学组,等.中国脂肪性肝病诊疗规范化的专家建议(2019年修订版).中华肝脏病杂志, 2019, 27(10):748-753. [10] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版).中华糖尿病杂志, 2021, 13(4):315-409. [11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186. [12] Lee CH, Lui DT, Lam KS. Non-alcoholic fatty liver disease and type 2 diabetes: an update. J Diabetes Investig, 2022,13(6):930-940. [13] Yan J, Yao B, Kuang H,et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology, 2019,69(6):2414-2426. [14] Isaacs S. Nonalcoholic fatty liver disease. Endocrinol Metab Clin North Am, 2023,52(1):149-164. [15] 赵玲玲,王贝贝,姚勇利,等.T2DM合并非酒精性脂肪性肝病伴进展性肝纤维化患者血清抵抗素和TyG指数变化及其临床意义探讨.实用肝脏病杂志, 2023, 26(3):356-359. [16] Ramdas Nayak VK, Satheesh P. Triglyceride glucose (TyG) index: a surrogate biomarker of insulin resistance. J Pak Med Assoc,2022,72(5):986-988. [17] Saiki A, Yamaguchi T, Sasaki A, et al. Background characteristics and diabetes remission after laparoscopic sleeve gastrectomy in Japanese patients with type 2 diabetes stratified by BMI: subgroup analysis of J-SMART. Diabetol Int, 2021,12(3):303-312. [18] Yan J, Yao B, Kuang H,et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology, 2019,69(6):2414-2426. [19] Alizargar J, Bai CH, Hsieh NC,et al. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol, 2020,19(1):8-9. [20] 刘奕婷,王巍,佟静,等.甘油三酯葡萄糖指数与非酒精性脂肪性肝病的关联性研究.中华肝脏病杂志, 2021, 29(5):451-455. |